Consensus Relmada Therapeutics, Inc. OTC Markets

Stocks

RLMD

US75955J4022

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 15:46:36 2026-09-03 EDT			5-day change	1st Jan Change
4.360 ^USD	0.00%		+8.91%	+139.13%

08-06	Relmada Therapeutics, Inc., Q2 2026 Earnings Call, Aug 06, 2026
08-06	Relmada Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Evolution of the Average Target: Relmada Therapeutics, Inc.

Evolution of the Target Price: Relmada Therapeutics, Inc.

Changes in Analyst Recommendations: Relmada Therapeutics, Inc.

f9adc8e.JiMqvnyxg78PVWWAN9oHI9F2XagNVa1nTCEWzuvSHAE.SGdexxPb5fFsNlbwVYNiaOlPbJhrBIBXI3EvpZqjdnF2ThLmCMi090IKPA~ecd39c251ae97b1bb7518ffdba200750

Analysts' recommendations: Relmada Therapeutics, Inc.

06-18	HC Wainwright Initiates Relmada Therapeutics at Buy With $12 Price Target	MT
03-24	Piper Sandler Initiates Coverage on Relmada Therapeutics With Overweight Rating	MT
11-19	Mizuho Upgrades Relmada Therapeutics to Outperform From Neutral	MT
11-06	Relmada Therapeutics Insider Bought Shares Worth $299,200, According to a Recent SEC Filing	MT
11-04	Relmada gets FDA support for two registrational study paths for NDV-01 in non-muscle invasive bladder cancer	RE
11-04	Relmada Therapeutics, Inc. Announces Fda Feedback Supporting 2 Separate Acceptable Registrational Study Paths for Ndv-01 in Non-Muscle Invasive Bladder Cancer	CI
24-12-05	Mizuho Downgrades Relmada Therapeutics to Neutral From Outperform, Adjusts Price Target to $1 From $23	MT
24-12-04	Leerink Partners Downgrades Relmada Therapeutics to Market Perform From Outperform, $1 Price Target; Shares Plummet	MT
24-09-17	Jefferies Upgrades Relmada Therapeutics to Buy From Hold, Price Target is $13	MT
24-06-05	Goldman Sachs Downgrades Relmada Therapeutics to Sell From Neutral With $2 Price Target	MT
23-01-23	SVB Securities Cuts Price Target on Relmada Therapeutics to $10 From $42, Maintains Outperform Rating	MT
22-12-09	Oppenheimer Reiterates Relmada Therapeutics Perform Rating, Removes $7 Price Target	MT
22-10-14	Goldman Sachs Downgrades Relmada Therapeutics to Neutral From Buy, Adjusts Price Target to $8 From $81	MT
22-10-14	Guggenheim Downgrades Relmada Therapeutics to Neutral From Buy	MT
22-10-13	Truist Securities Downgrades Relmada Therapeutics to Hold From Buy, Adjusts Price Target to $10 From $90	MT
22-10-13	Oppenheimer Downgrades Relmada Therapeutics to Perform From Outperform, Adjusts Price Target to $7 From $64	MT
22-09-23	Goldman Sachs Adjusts Price Target on Relmada Therapeutics to $81 From $49, Reiterates Buy Rating	MT
22-09-06	Guggenheim Adjusts Price Target on Relmada Therapeutics to $60 From $50, Reiterates Buy Rating	MT
22-08-12	Goldman Sachs Adjusts Price Target for Relmada Therapeutics to $49 From $47, Maintains Buy Rating	MT
22-05-09	Oppenheimer Adjusts Relmada Therapeutics' Price Target to $64 From $75, Maintains Outperform Rating	MT
22-03-24	Goldman Sachs Adjusts Relmada Therapeutics' Price Target to $53 from $69, Keeps Buy Rating	MT
21-12-20	SVB Leerink Adjusts Relmada Therapeutics' Price Target to $42 from $50, Keeps Outperform Rating	MT
21-11-18	Mizuho Securities Starts Relmada Therapeutics at Buy With $50 Price Target	MT
21-07-27	Relmada Therapeutics : Truist Securities Adjusts Relmada Therapeutics PT to $90 From $75, Maintains Buy Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	WUXI APPTEC CO., LTD.					+19.41%
	ARGENX SE					+9.33%
	INSMED INCORPORATED					+58.08%
	WUXI BIOLOGICS (CAYMAN) INC.					+16.48%
	BIONTECH SE					+15.93%
	GENMAB A/S					+11.59%
	PHARMAESSENTIA CORPORATION					+7.07%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+25.44%
	EXELIXIS, INC.					-8.27%
	Average					+17.23%
	Weighted average by Cap.					+17.86%